BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  AstraZeneca Touts Profits While Slashing Programs

  In the waning weeks of the fourth quarter of the 2020 fiscal year, AstraZeneca terminated several clinical programs, including some oncology and heart-related studies, as well as one COVID-19 related trial.

  February 11, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  BioSpace Movers & Shakers, Feb. 12

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  February 11, 2021

   · 

  6 min read

   · 

  Alex Keown
• 

  Drug Development

  COVID-19 Vaccine Program Hiccups, Misses and Disasters

  There are some big surprises among the list of major players in the vaccine space who either dropped their programs or have been significantly delayed.

  February 11, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Research Roundup: COVID-19 Brain Fog and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  February 11, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Ensoma Launches with $70 Million Series A and Takeda Licensing Deal

  As part of the Takeda deal, Ensoma will do preclinical research for therapies in up to five rare disease indications, and both companies will work on Investigational New Drug-enabling studies.

  February 11, 2021

   · 

  2 min read

   · 

  Mark Zipkin
• 

  Business

  Immunai Gets Series A Funding for Genomics Database Advancements

  Immunai today announced it has received $60 million in Series A funding, bringing its total funding since inception in December 2018 to $80 million.

  February 11, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  Policy

  Fresenius Kabi Hid “Dirty Laundry” from FDA, Pleads Guilty to Criminal Charges

  The cancer drugmaker pled guilty of violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to investigators in federal court.

  February 11, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  FDA

  FDA Makes Landmark Approval for ANGPTL-3 Inhibitors

  The U.S. FDA approved Regeneron’s monoclonal antibody Evkeeza (evinacumab-dgnb) as an add-on treatment for adult and pediatric patients ages 12 and above with homozygous familial hypercholesterolemia (HoFH).

  February 11, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  How to Handle Time Off When You Work from Home and Can’t Travel

  It’s easy to feel guilty about taking time off when you’re working from home and not physically going on vacation. But your brain needs that vacation.

  February 11, 2021

   · 

  2 min read

   · 

  Laura Brothers
• 

  Drug Development

  New Vaccine Formulation Shows Promise for Alzheimer’s Target

  Switzerland-based AC Immune SA announced positive interim results from its ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.

  February 11, 2021

   · 

  3 min read

   · 

  Mark Terry